Shots: The EU approval is based on results of P-III PROSPER trial assessing Xtandi+ ADT vs. PBO + ADT in patients with nmCRPC and PSA level The P-III PROSPER trial resulted in mPFS (36.6 vs 14.7mos.). In June, 2013 Xtandi received its first EU approval for mCRPC in men Xtandi PO is qd androgen receptor […]Read More
